| [1] |
Chen W, Zheng R, Zhang S,et al. Report of cancer incidence and mortality in China, 2010 [J]. Ann Transl Med, 2014, 2(7): 61.
|
| [2] |
André T, Boni C, Mounedji-Boudiaf L, et al.Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J]. N Engl J Me, 2004, 350(23): 2343-2351.
|
| [3] |
André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial [J]. J Clin Oncol, 2009, 27(19): 3109-3116.
|
| [4] |
NCCN Guideline Panel. National Comprehensive Cancer Network Guidelines in Oncology (NCCN Guidelines). Colon cancer, 2018, Version 4.
|
| [5] |
FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer [J]. J Clin Oncol 2019, 37(suppl): abstr 3504.
|
| [6] |
Jianmin Xu, Jianguo Xia, Yan Gu, et al. Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) Reduces the Occurrence of Metachronous Liver Metastasis after Curative Colorectal Cancer: A Prospective, Multi-Center, Randomized Controlled Trial [J]. J Clin Oncol, 2015, 33(suppl 3): abstr 511.
|
| [7] |
Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial [J]. Lancet Oncol, 2012, 13(11): 1152-1160.
|
| [8] |
Gunderson LL, Jessup JM, Sargent DJ,et al. Revised T N categorization for colon cancer based on national survival outcomes data [J]. J Clin Oncol, 2010, 28(2): 264-271.
|
| [9] |
Quasar Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study [J]. Lancet, 2007, 370(9604): 2020-2029.
|
| [10] |
Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials [J]. J Clin Oncol, 2009, 27(6): 872-877.
|
| [11] |
André T, de Gramont A, Vernerey D,et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study [J]. J Clin Oncol, 2015, 33(35): 4176-4187.
|
| [12] |
Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2013, 24 (Suppl 6): vi64-72.
|
| [13] |
O'Connor ES, Greenblatt DY, LoConte NK,et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features [J]. J Clin Oncol,2011,29(25):3381-3388.
|
| [14] |
Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients [J]. J Clin Oncol, 2015, 33(16): 1787-1796.
|
| [15] |
Wells KO, Hawkins AT, Krishnamurthy DM,et al. Omission of Adjuvant Chemotherapy Is Associated With Increased Mortality in Patients With T3N0 Colon Cancer With Inadequate Lymph Node Harvest [J]. Dis Colon Rectum, 2017, 60(1): 15-21.
|
| [16] |
Nash GM, Gimbel M, Cohen AM,et al. KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer [J]. Ann Surg Oncol, 2010, 17(2): 416-424.
|
| [17] |
Sargent DJ, Marsoni S, Monges G, et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer[J]. J Clin Oncol,2010,28(20):3219-3226.
|
| [18] |
Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [J]. J Clin Oncol, 2011, 29(10): 1261-1270.
|
| [19] |
Ribic CM, Sargent DJ, Moore MJ,et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer [J]. N Engl J Med, 2003, 349(3): 247-257.
|
| [20] |
Buecher B, Cacheux W, Rouleau E,et al. Role of microsatellite instability in the management of colorectal cancers [J]. Dig Liver Dis, 2013, 45(6): 441-449.
|
| [21] |
Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant oxaliplatin-based therapy (3 vs 6 months) for patients with high-risk stage II colorectal cancer [J]. J Clin Oncol, 2019, 37(suppl): abstr 3501.
|
| [22] |
Schmoll HJ, Tabernero J, Maroun J,et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled Phase III trial [J]. J Clin. Oncol, 2015, 33(32): 3733-3740.
|
| [23] |
Twelves C, Scheithauer W, Mckendrick J,et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy [J]. Ann. Oncol, 2011, 23(5): 1190-1197.
|
| [24] |
Grothey A, Sobrero AF, Shields AF,et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer [J]. N Engl J Med, 2018,378(13):1177-1188.
|
| [25] |
Yamaguchi K, Kunieda T, Sato Y,et al. Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801 [J]. Ann Oncol, 2016, 27 (suppl_6): 469PD.
|
| [26] |
Saltz LB, Niedzwiecki D, Hollis D,et al.Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 [J]. J Clin Oncol, 2007, 25(23): 3456-3461.
|
| [27] |
Ychou M, Raoul JL, Douillard JY,et al. A Phase III randomised trial of LV5FU2＋irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) [J]. Ann Oncol, 2009, 20(4): 674-680.
|
| [28] |
Van Cutsem E, Labianca R, Bodoky G,et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 [J]. J Clin Oncol, 2009, 27(19): 3117-3125.
|
| [29] |
de Gramont A, Van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a Phase 3 randomised controlled trial [J]. Lancet Oncol, 2012, 13(12): 1225-1233.
|
| [30] |
Allegra CJ, Yothers G, O'Connell MJ,et al.Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon:results of NSABP protocol C-08 [J]. J Clin Oncol, 2011, 29(1): 11-16.
|
| [31] |
Alberts SR, Sargent DJ, Nair S,et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial [J]. JAMA, 2013, 307(13): 1383-1393.
|
| [32] |
Taieb J, Tabernero J, Mini E,et al. Oxalipl-atin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised Phase 3 trial [J]. Lancet Oncol, 2014, 15(8): 862-873.
|
| [33] |
Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial [J]. JAMA Oncol, 2016, 2(5): 643-653.
|
| [34] |
Tetsuya H, Yasuhiro S, Junki M,et al. Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine (cape) in patients with stage III colon cancer (CC): Results of Japan Clinical Oncology Group study (JCOG0910) [J]. J Clin Oncol, 2015, 33(suppl): abstr 3512.
|
| [35] |
Deborah S, Shicheng W, Gabriel B,et al. The relationship between primary tumor sidedness and prognosis in colorectal cancer [J]. J Clin Oncol, 2016, 34(suppl): abstr 3505.
|
| [36] |
Shah MA, Renfro LA, Allegra CJ, et al. Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database [J]. J Clin Oncol, 2016, 34(8): 843-853.
|
| [37] |
Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer [J]. J Clin Oncol, 2011, 29(1): 17-24.
|
| [38] |
Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [J]. J Clin Oncol, 2011, 29(10): 1261-1270.
|
| [39] |
Popovici V, Budinska E, Bosman FT, et al. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer [J]. BMC Cancer, 2013, 13: 439.
|
| [40] |
Yancik R, Wesley MN, Ries LA,et al.Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study [J]. Cancer, 1998, 82(11): 2123-2134.
|
| [41] |
Hanna NN, Onukwugha E, Choti MA, et al. Comparative analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare data [J]. Colorectal Dis, 2012, 14(1): 48-55.
|
| [42] |
Yothers G, O'Connell MJ, Allegra CJ,et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses [J]. J Clin Oncol, 2011, 29(28): 3768-3774.
|
| [43] |
Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment [J]. J Clin Oncol, 2012, 30(27): 3353-3360.
|
| [44] |
Haller DG, O'Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials [J]. Ann Oncol, 2015, 26(4), 715-724.
|
| [45] |
Deboever G, Hiltrop N, Cool M, et al. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity [J]. Clin Colorectal Cancer, 2013, 12(1): 8-14.
|
| [46] |
Peng J, Dong C, Wang C, et al. Cardiotoxicity of 5fluorouracil and capecitabine in Chinese patients: a prospective study [J]. Cancer Commun (Lond), 2018, 38(1): 22.
|
| [47] |
Saif MW, Shah MM, Shah AR, et al. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin [J]. Drug Saf, 2009, 8(2): 191-202.
|
| [48] |
Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer [J]. Sci Transl Med, 2016, 8(346): 346ra92.
|
| [49] |
Tarazona N, Gimeno-Valiente F, Gambardella V, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer [J]. Ann Oncol, 2019, Sep 28. pii: mdz390 [Epub ahead of print].
|
| [50] |
Taieb J, Taly V, Vernerey D, et al. Analysis of circulating tumor DNA(ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial:prognostic and predictive value for adjuvant treatment duration [J]. Ann Oncol, 2019, 30(suppl 5): v851-934.
|